Clinical Trials Logo

Esophagus SCC clinical trials

View clinical trials related to Esophagus SCC.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04625543 Withdrawn - Esophagus SCC Clinical Trials

Neoadjuvant Immunotherapy to ESCC

Start date: December 2020
Phase: Phase 2
Study type: Interventional

Currently, surgery after neoadjuvant chemoradiotherapy is the standard treatment for patients with locally advanced esophageal cancer, but the recurrence rate is high and the 5-year survival rate is low. Immunotherapy shows a potential treatment for esophageal cancer. Immunocheckpoint (PD-1/PD-L1) inhibitors can activate tumor immunity. The guidelines have recommended it as a sencond-line therapy. However, there is still lack of the evidence for its efficacy as a neoadjuvant therapy. This study is to conduct a randomized controlled, open label, phase II clinical trial to evaluate the efficacy and safety of neoadjuvant immnotherapy combined with neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) patient with PD-L1 (CPS>=10%) positive.